Antiviral 2,5-disubstituted imidazo[4,5-c]pyridines: From anti-pestivirus to anti-hepatitis C virus activity

2007 ◽  
Vol 17 (2) ◽  
pp. 390-393 ◽  
Author(s):  
Gerhard Puerstinger ◽  
Jan Paeshuyse ◽  
Erik De Clercq ◽  
Johan Neyts
Hepatology ◽  
2009 ◽  
Vol 50 (1) ◽  
pp. 6-16 ◽  
Author(s):  
Leen Delang ◽  
Jan Paeshuyse ◽  
Inge Vliegen ◽  
Pieter Leyssen ◽  
Susan Obeid ◽  
...  

2009 ◽  
Vol 100 (10) ◽  
pp. 1943-1950 ◽  
Author(s):  
Kaku Goto ◽  
Koichi Watashi ◽  
Daisuke Inoue ◽  
Makoto Hijikata ◽  
Kunitada Shimotohno

Heterocycles ◽  
2010 ◽  
Vol 81 (6) ◽  
pp. 1419 ◽  
Author(s):  
Kazuyuki Sugita ◽  
Masanori Baba ◽  
Mohammed T. A. Salim ◽  
Mika Okamoto ◽  
Hiroshi Aoyama ◽  
...  

2002 ◽  
Vol 25 ◽  
pp. 99-102
Author(s):  
Alexander C Haushofer ◽  
René Hauer ◽  
Harald Brunner ◽  
Ursula Köller ◽  
Doris Trubert-Exinger ◽  
...  

2006 ◽  
Vol 50 (10) ◽  
pp. 3444-3446 ◽  
Author(s):  
Lotte Coelmont ◽  
Jan Paeshuyse ◽  
Marc P. Windisch ◽  
Erik De Clercq ◽  
Ralf Bartenschlager ◽  
...  

ABSTRACT Ribavirin antagonizes the in vitro anti-hepatitis C virus (HCV) activity of the pyrimidine nucleoside analogue 2′-C-methylcytidine, the active component of the experimental anti-HCV drug valopicitabine. In contrast, the combination of ribavirin with either the purine nucleoside analogue 2′-C-methyladenosine or the HCV protease inhibitor VX-950 resulted in an additive antiviral activity. These findings may have implications when planning clinical studies with valopicitabine.


2016 ◽  
Vol 128 ◽  
pp. 60-70 ◽  
Author(s):  
Chih-Hua Chao ◽  
Ju-Chien Cheng ◽  
De-Yang Shen ◽  
Hui-Chi Huang ◽  
Yang-Chang Wu ◽  
...  

2010 ◽  
Vol 18 (16) ◽  
pp. 6143-6148 ◽  
Author(s):  
Grazia Sellitto ◽  
Aurora Faruolo ◽  
Paolo de Caprariis ◽  
Sergio Altamura ◽  
Giacomo Paonessa ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document